Fulgent Business Model Canvas

Designing targeted panels for rare disease, oncology, reproductive and infectious use cases, Fulgent prioritizes breadth and clinical relevance while leveraging sequencing costs near USD 600–1,000 per genome (2024) to optimize economics. Analytical and clinical validation follows CLIA, CAP and FDA-aligned standards with performance targets typically exceeding 99% sensitivity for SNVs and high reproducibility. Continuous iteration adds new genes and biomarkers quarterly to capture emerging evidence. Detailed validation dossiers and health‑economic documentation support payer coverage and guideline inclusion.

High-throughput sequencing operations at Fulgent cover sample accessioning, automated extraction, library prep, and multiplexed NGS runs to support clinical panels and large-scale screens. Automation drives scale and consistency, enabling throughput reported in 2024 alongside corporate revenue of $486.5 million. Rigorous QC protocols aim to keep reruns minimal and TAT optimized to meet clinical turnaround targets.

CLIA and CAP accreditation—with roughly 260,000 CLIA-certified U.S. laboratory entities and about 8,000 CAP-accredited programs globally—underpin clinical credibility for Fulgent. Redundant facility capacity enables surge response. High-throughput instrumentation and automation (eg, Illumina NovaSeq 6000 platforms delivering up to ~20 billion reads per run) drive daily throughput. Rigorous environmental controls and validated temperature/humidity monitoring preserve sample integrity.

Proprietary bioinformatics platform runs optimized algorithms for alignment, variant calling and CNV detection, feeding an interpretation rules engine backed by curated databases updated weekly (2024). Scalable cloud architecture delivers rapid compute at ≥1,000 samples/day with 99.95% availability, sub‑hour median pipeline runtime, and APIs for integration and reporting with <200 ms median latency.

Clear, guideline-aligned reports (ACMG standards) deliver treatment-informed results and therapy-matching where applicable; genomic testing yields up to ~40% diagnostic rates and can shorten the typical 4–7 year diagnostic odyssey, enabling risk stratification, targeted therapy options and measurable gains in patient outcomes and clinician confidence.

Broad, modular test menu covers panels for rare disease, oncology, reproductive health and infectious diseases, enabling clinicians to consolidate testing. Customizable content supports institution-specific protocols and EMR workflows. Reflex testing options reduce turnaround and streamline care pathways. A future-ready R&D pipeline integrates emerging biomarkers to keep the menu clinically current.

Named reps guide onboarding and partner with clients to drive site-level growth, aligning milestones with operational capacity.

Quarterly business reviews and KPI tracking are used to optimize service delivery and adapt workflows to evolving needs.

Rapid escalation paths ensure priority issue resolution, while account teams design tailored solutions for each site’s workflow and compliance requirements.

Clinical support and genetic counseling provide access to experts for case review and result interpretation, with pre- and post-test counseling where applicable to ensure appropriate test selection and follow-up. Educational resources and regular office hours bolster clinician confidence and patient trust, reducing misorders. This approach aligns with a global genetic testing market near USD 18 billion in 2024 and drives higher-quality utilization.

Field reps engage hospitals, clinics and labs—targeting about 6,100 US hospitals and thousands of outpatient sites—to build institutional relationships. Demos and pilots (short-term lab validations) lower clinical adoption barriers and provide operational proof points. Contracting aligns volume tiers and pricing to secure predictable revenue streams. Ongoing technical and account support sustains utilization and expands test mix.

Digital portal with online ordering and result delivery plus APIs for EHR/LIS integrations reduces manual steps and enables automated notifications that improve visibility and turnaround. Fulgent serves all 50 states and trades on NASDAQ: FLGT, supporting scalable national operations without heavy field presence. The platform handles high-volume testing workflows while pushing results and orders into EHRs/LIS in real time.

Oncologists and cancer centers require biomarker-driven treatment guidance where tumor and germline testing inform therapy selection and hereditary risk management; rapid turnaround time (clinically, under 7 days when possible) directly alters regimen decisions. CDx alignment is critical—as of 2024 the FDA has authorized more than 50 companion diagnostics, driving adoption and reimbursement discussions.

Geneticists, neurologists and pediatricians seek definitive diagnoses for rare disease patients, where the diagnostic odyssey averages 5–7 years. Exome and targeted panel testing deliver diagnostic yields of roughly 25–40% and significantly shorten time to diagnosis versus serial testing. Trio analysis and phenotype-driven interpretation can boost yield by about 10–15% while clinical phenotype tools prioritize variants. Long-term follow-up data informs prognosis and can alter management in up to 60% of diagnosed cases.

Reagents and consumables—nucleic acids extraction kits, library prep reagents, sequencing flow cells and disposables—represent the largest variable COGS line for Fulgent, with volume-based supplier pricing and contract tiers directly driving per-sample margins. Rigorous inventory management (just-in-time ordering, automated reorder points) prevents costly stockouts and rush freight. Structured waste-reduction and reuse programs lower disposal and repurchase frequency, tightening COGS and stabilizing unit economics.

Labor and staffing costs cover ASCP-credentialed lab technologists, molecular scientists, genetic counselors, and bioengineers plus field and customer-support teams to sustain service delivery. Continuous training and retention programs reduce diagnostic error rates and protect CLIA/CAP compliance. 24/7 shift coverage and scalable staffing models ensure throughput for high-volume sequencing and reporting.

Payments come from commercial insurers and government programs, with in-network contracting driving predictable cash flows through agreed fee schedules. Prior authorization support increases approval rates for high-cost tests, reducing write-offs. Active denial management and resubmission workflows protect revenue yield and shorten days receivable. Integration with payer portals improves collection efficiency.

Fulgent’s self-pay and patient-paid testing emphasizes transparent pricing for uninsured or non-covered tests, with clear price lists and eligibility checks; payment plans and targeted discounts are offered to improve affordability. Direct-to-patient programs are used where regulation permits, and this channel helps reach the roughly 8–9% of U.S. residents who lack insurance, expanding access beyond payer limits.